Imagion Biosystems Limited has announced a supplementary prospectus (Supplementary Prospectus) which shall be read with the prospectus dated 28 October 2019 (Prospectus) and issued by Imagion Biosystems Limited (Company or IBX).
Read the supplementary prospectus.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal